Endocrine Abstracts

Secondary osteoporosis accounts for 10–20% of the causes of osteoporosis in menopausal women. The search for a possible etiology should not be neglected before considering the therapeutic management of any osteoporosis. There is no consensus on the first-line biological tests to be prescribed.

Goal: Determine biological abnormalities in postmenopausal women with osteoporosis.

Patients/methods: Postmenopausal women are enrolled, the mean age is 65.5±8.9 years. 305 patients are classified as osteoporotic according to the WHO criteria (T-score ≤2.5). NFS, VS, CRP, serum calcium, phosphoric acid, 24-hour calcium, total alkaline phosphatase, parathyroid hormone (PTH), serum protein electrophoresis, serum creatinine, liver function test, fasting blood glucose.

Results: 6.2% (19/305) patients had an abnormality.

Distribution of anomalies: Monoclonal gammopathy five cases: two myeloma, two MGUS, one unlabeled case

- HPT I: seven cases (two parathyroid adenomas confirmed by the anapath)

- 1 cases rheumatoid arthritis

- diabetes type two unknown: six cases, one case of intolerance to carbohydrates

Discussion/conclusion: In the presence of a low BMD, it is recommended that a diagnostic survey should be carried out, including physical examination, clinical examination and routine biological examinations, in order to eliminate malignant or metabolic osteopathy and to investigate the causes of secondary osteoporosis. In our study targeting a population of postmenopausal osteoporotic women followed in consultation, the discovery by biological examination of a new condition that can lead to bone demineralization is quite common.